Akorn Pharmaceuticals - Comprehensive Analysis Report

Summary

Akorn Pharmaceuticals, formerly Akorn Inc., was an American generic pharmaceutical manufacturer founded in 1971 and based in Lake Forest, Illinois. The company's mission historically centered on improving lives through the quality, availability, and affordability of its products, focusing on niche markets such as ophthalmology, anesthesia, antidotes, and rheumatology. Prior to its financial difficulties and eventual dissolution, Akorn was a component of the NASDAQ Biotechnology Index, known for developing, manufacturing, and marketing generic and branded prescription pharmaceuticals, as well as animal and consumer health products. The company ceased all U.S. operations and laid off its entire workforce in February 2023 after filing for Chapter 7 bankruptcy, leading to its liquidation.

1. Strategic Focus & Objectives

Core Objectives

Historically, Akorn's main business objectives included the development, manufacture, and marketing of a diverse portfolio of pharmaceutical products. The company aimed to ensure the quality, availability, and affordability of these products, contributing to improved patient outcomes. Its strategy involved both internal product development and growth through acquisitions and licensing of specialty products.

Specialization Areas

Akorn specialized in niche pharmaceutical markets, particularly those requiring difficult-to-manufacture sterile and non-sterile dosage forms. Its key areas of expertise included:

• Ophthalmology: A broad range of diagnostic and therapeutic pharmaceuticals, as well as surgical instruments.

• Anesthesia & Antidotes: Critical medications for various medical procedures and emergency care.

• Rheumatology: Products addressing conditions within this therapeutic area.

• Complex Dosage Forms: Expertise in ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays.

Target Markets

Akorn primarily targeted:

• Prescription Pharmaceuticals Segment: Focused on sterile ophthalmics, injectables, inhalants, and non-sterile oral liquids, topicals, and nasal sprays.

• Consumer Health Segment: Encompassed animal health and over-the-counter products, including both branded and private-label offerings.

• The company’s sales efforts were directed at physicians, optometrists, wholesalers, group purchasing organizations, and pharmacies across the United States.

2. Financial Overview

Funding History

Akorn Pharmaceuticals encountered significant financial challenges, culminating in its cessation of operations.

• February 2023: Filed for Chapter 7 bankruptcy, leading to the immediate cessation of all U.S. operations, liquidation, and layoff of its entire workforce. The company listed over $100 million in debt.

• May 2020: Filed for Chapter 11 bankruptcy, entering into a Restructuring Support Agreement with lenders, representing over 75 percent of its secured debt. This was intended to facilitate an in-court sale and address litigation.

• April 2017: Fresenius agreed to acquire Akorn for $4.3 billion, but these plans were abandoned due to Akorn's inability to meet basic acquisition requirements.

• May 22021: Announced an agreement to sell its Consumer Health business to an affiliate of Prestige Consumer Healthcare Inc. for $230 million in cash. This sale aimed to optimize Akorn's core prescription drug portfolio. Brands included TheraTears®, Diabetic Tussin®, Mag-Ox®, Multi-betic®, and Zostrix®.

• March 2022: Seven of its branded ophthalmic products were acquired by Théa Pharma, Inc.

• September 2022: Agreed to pay $7.9 million to resolve allegations of fraudulent billing related to claims that three of its generic drugs were covered by Medicare Part D.

3. Product Pipeline

Key Products/Services

Akorn's product portfolio historically encompassed a wide range of pharmaceuticals, emphasizing specialty and generic markets.

• Ophthalmic Products: Included an extensive line of diagnostic and therapeutic pharmaceuticals, such as mydriatics, cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, antibiotics, anti-infectives, steroids, glaucoma medications, decongestants/antihistamines, and anti-edema medications. These were developed to address various eye conditions, from diagnosis to treatment.

• Injectables: Comprised various pharmaceutical solutions, ointments, gels, and injectables, including antidotes, anti-infectives, and controlled substances. These were crucial for hospital and clinical settings.

• Other Dosage Forms: Developed non-sterile oral liquids, topicals, nasal sprays, and inhalants targeting a range of therapeutic categories.

• Consumer Health Products: Before its sale, the Consumer Health business included brands like TheraTears®, Diabetic Tussin®, Mag-Ox®, Multi-betic®, and Zostrix®, catering to over-the-counter and animal health markets.

• Bimatoprost Ophthalmic Solution, 0.03%: Received Abbreviated New Drug Application (ANDA) approval from the FDA in October 2018, targeting glaucoma patients.

• Contract Manufacturing Services: Provided through its injectable division, Taylor Pharmaceuticals, offering manufacturing expertise to other pharmaceutical companies.

4. Technology & Innovation

Technology Stack

Akorn maintained a strong focus on developing and manufacturing specialty pharmaceuticals, particularly those requiring complex sterile and non-sterile dosage forms.

• Core Platforms and Technologies: Engaged in the development and production of a diverse range of dosage forms including ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays.

• Proprietary Developments: Utilized R&D facilities to develop a pipeline of new products, focusing on niches that required specialized manufacturing capabilities.

• Scientific Methodologies: Conducted research and development aimed at creating pharmaceutical solutions, ointments, gels, and injectables, adhering to strict pharmaceutical standards.

• Technical Capabilities: Possessed US-FDA approved manufacturing facilities in Decatur, Illinois, and an R&D Center in Vernon Hills, Illinois, ensuring compliance and quality in production. A manufacturing plant in Somerset, New Jersey, was closed in July 2022.

5. Leadership & Management

Executive Team

• Douglas S. Boothe: Served as the President and Chief Executive Officer.

• Beth Zelnick Kaufman: Held the position of Chief Legal Officer.

• Raj Rai: Served as Chief Executive Officer as of May 2016.

• Bruce Kutinsky, Pharm. D.: Joined Akorn as Senior Vice President of Corporate Strategy in 2010 and was named President of the Consumer Health Division upon its launch.

Recent Leadership Changes

• February 2023: Douglas Boothe, CEO, announced the company's Chapter 7 bankruptcy filing, leading to an immediate cessation of all operations and employee layoffs. This marked the final leadership change as the company ceased to exist as an operating entity.

6. Talent and Growth Indicators

Hiring Trends and Workforce

Following its Chapter 7 bankruptcy filing in February 2023, Akorn Pharmaceuticals ceased all operations and liquidated, resulting in the layoff of its entire workforce. The company had reported 2,238 employees at the end of 2019. Due to the cessation of operations and liquidation, there are no current hiring trends, open positions, or growth indicators for Akorn Pharmaceuticals as an ongoing entity. The Illinois Department of Labor (IDOL) initiated an investigation due to the company not filing a required 60-day notice with employees and government entities regarding the mass layoffs.

7. Social Media Presence and Engagement

Given the company's Chapter 7 bankruptcy and cessation of all operations in February 2023, Akorn Pharmaceuticals no longer maintains an active social media presence or engagement.

8. Recognition and Awards

Industry Recognition

Information regarding specific industry awards and recognitions for Akorn Pharmaceuticals is not consistently available across recent publicly accessible records, particularly in the context of its later financial challenges and dissolution. The company was historically a component of the NASDAQ Biotechnology Index prior to its financial difficulties.

9. Competitive Analysis

Major Competitors

When Akorn Pharmaceuticals was operational, it competed in various pharmaceutical segments.

• Ophthalmic Marketplace: Faced competition from over 300 companies worldwide, including Blount International Inc. and Carl Zeiss Inc.

• General Pharmaceutical and Ophthalmic Segments: Competed with major players such as Merck & Co., Novartis AG, Bristol-Myers Squibb Company, Glaxo Wellcome PLC, Alcon Laboratories, Bausch & Lomb, and Allergan.

• Generic and Specialty Pharmaceuticals: Was a competitor to Taro Pharmaceutical Industries.

10. Market Analysis

Market Overview

Akorn historically operated within the generic pharmaceutical market, which accounts for approximately 90% of US drug prescriptions. The company's trajectory was influenced by broader industry dynamics, including significant scrutiny related to manufacturing quality and regulatory compliance.

• Market Challenges: The generics industry, including Akorn, faced financial strains and received warning letters from the FDA in 2019 for violations of current good manufacturing practice (CGMP) regulations.

• Impact of Closure: The abrupt shutdown of Akorn contributed significantly to drug shortages, especially affecting sterile generic injectables and sterile ophthalmics, which are complex to manufacture. Akorn was a key manufacturer of diagnostic ophthalmic agents such as cyclopentolate, tropicamide, and phenylephrine, holding a substantial share of U.S. production for these drugs. It also held over 80% of the fluorescein market before ceasing production. The company’s closure highlighted severe financial strains plaguing the generics industry, leading to drug supply chain disruptions.

11. Strategic Partnerships

Akorn engaged in several significant acquisitions and partnerships throughout its history to expand its product offerings and market presence.

• Hi-Tech Pharmacal: Acquired this rival company in 2013, expanding its portfolio.

• Merck: Acquired US rights for AzaSite, Cosopt, and Cosopt PF from Merck in November 2013.

• Santen: Purchased US rights for Betimol, a prescription glaucoma drug, from Santen in January 2014.

• Advanced Vision Research, Inc.: Acquired in May 2011 for $26 million, gaining brands like TheraTears® and MacuTrition®. Akorn had previously been a primary contract manufacturer for Advanced Vision Research.

12. Operational Insights

Historically, Akorn’s strategic advantage stemmed from its specialization in niche pharmaceutical markets and its ability to develop and manufacture difficult-to-manufacture sterile and non-sterile dosage forms.

• Competitive Advantages: Focus on complex dosage forms and specialized therapeutic areas allowed differentiation in the competitive generic pharmaceuticals landscape.

• Operational Strengths: A vertically integrated structure encompassing research and development, manufacturing, distribution, and sales and marketing supported its operations in ophthalmology, anesthesia, antidotes, and rheumatology. Its US-FDA approved manufacturing facilities and R&D centers were critical for product development and supply chain.

• Areas for Improvement (historical): The company faced significant regulatory compliance issues, including FDA warning letters, and ultimately severe financial strain that led to bankruptcy.

13. Future Outlook

Strategic Roadmap

Due to Akorn Pharmaceuticals filing for Chapter 7 bankruptcy in February 2023 and subsequently ceasing all U.S. operations and liquidating, there are no current strategic opportunities, growth strategies, expansion opportunities, or future directions for the company as an ongoing business entity. The company’s assets, including product lines, intellectual property, and manufacturing capabilities, have been or are in the process of being liquidated. These assets may present restructuring and acquisition potential for other industry players.